Olema Pharmaceuticals inc (OLMA)
10.70
-0.20
(-1.83%)
USD |
NASDAQ |
May 07, 10:59
Olema Pharmaceuticals Research and Development Expense (Quarterly): 25.87M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 25.87M |
| September 30, 2023 | 19.45M |
| June 30, 2023 | 17.99M |
| March 31, 2023 | 22.83M |
| December 31, 2022 | 21.58M |
| September 30, 2022 | 17.63M |
| June 30, 2022 | 27.05M |
| March 31, 2022 | 16.01M |
| December 31, 2021 | 15.98M |
| Date | Value |
|---|---|
| September 30, 2021 | 12.52M |
| June 30, 2021 | 11.91M |
| March 31, 2021 | 10.69M |
| December 31, 2020 | 6.289M |
| September 30, 2020 | 4.673M |
| June 30, 2020 | 1.947M |
| March 31, 2020 | 0.795M |
| December 31, 2019 | 0.91M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.795M
Minimum
Mar 2020
27.05M
Maximum
Jun 2022
13.77M
Average
15.98M
Median
Dec 2021
Research and Development Expense (Quarterly) Benchmarks
| Geron Corp | 29.37M |
| Verastem Inc | 22.50M |
| Fate Therapeutics Inc | 31.82M |
| Karyopharm Therapeutics Inc | 39.38M |
| Alpine Immune Sciences Inc | 22.93M |